Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the appointment of Thomas M.
View HTML
Toggle Summary Anika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial Joints
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that regulatory authorities in Australia granted approval to
View HTML
Toggle Summary Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017 ,
View HTML
Toggle Summary Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
Deep international expertise to drive the Company's global expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the publication of data demonstrating that HYALOFAST ® , a
View HTML
Toggle Summary Anika Announces Appointment of Joseph Darling as President
Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Reports Strong Second Quarter 2017 Financial Results
MONOVISC U.S. End-User Sales Exceeded $100 Million at an Accelerated Pace CINGAL Phase III Clinical Trial Achieved Rapid Advancements BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on
View HTML
Toggle Summary Anika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that regulatory authorities in India granted approval to MONOVISC
View HTML
Toggle Summary Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
Company Expects Total Revenue Growth of 23% to 26% for Q2 2017 BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced
View HTML
Toggle Summary Anika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2017 financial results after the close of the market on Wednesday, July 26, 2017 and to hold a conference call the next day, Thursday, July 27, 2017 , at
View HTML